Immatics (IMTX) Other Gross PP&E Adjustments (2019 - 2025)
Immatics recorded quarterly Other Gross PP&E Adjustments of -$14.9 million in Q4 2025, up 7.11% quarter-over-quarter from -$16.0 million in Q3 2025, and down 4.47% year-over-year from -$15.6 million in Q4 2024.
Immatics' Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$14.9 million for Q4 2025.
- In Q4 2025, Other Gross PP&E Adjustments fell 4.47% year-over-year to -$14.9 million; the TTM figure through Dec 2025 stood at -$14.9 million (down 4.47% YoY), while the FY2025 annual figure was -$14.4 million, down 1.4% from the prior year.
- Other Gross PP&E Adjustments came in at -$14.9 million for Q4 2025 at Immatics, up from -$16.0 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$7.6 million in Q1 2021 to a low of -$16.4 million in Q1 2025.
- A 5-year average of -$13.6 million and a median of -$14.5 million in 2023 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments tumbled 81.94% in 2022 and gained 7.53% in 2024, its largest moves.
- Immatics' Other Gross PP&E Adjustments stood at -$11.4 million in 2021, then slipped by 16.44% to -$13.3 million in 2022, then declined by 7.68% to -$14.3 million in 2023, then gained by 0.5% to -$14.2 million in 2024, then declined by 4.47% to -$14.9 million in 2025.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$14.9 million, -$16.0 million, and -$16.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -14.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.88 Mn |
| Dec 31, 2025 | -14.88 Mn |
| Sep 30, 2025 | -16.02 Mn |
| Sep 30, 2025 | -16.02 Mn |
| Jun 30, 2025 | -16.37 Mn |
| Jun 30, 2025 | -16.37 Mn |
| Mar 31, 2025 | -16.39 Mn |
| Mar 31, 2025 | -16.39 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Sep 30, 2024 | -14.64 Mn |
| Sep 30, 2024 | -14.64 Mn |
| Jun 30, 2024 | -15.74 Mn |
| Jun 30, 2024 | -15.74 Mn |
| Mar 31, 2024 | -12.91 Mn |
| Mar 31, 2024 | -12.91 Mn |
| Dec 31, 2023 | -14.32 Mn |
| Dec 31, 2023 | -14.32 Mn |
| Sep 30, 2023 | -15.57 Mn |
| Sep 30, 2023 | -15.57 Mn |
| Jun 30, 2023 | -16.06 Mn |
| Jun 30, 2023 | -16.06 Mn |
| Mar 31, 2023 | -13.96 Mn |
| Mar 31, 2023 | -13.96 Mn |
| Dec 31, 2022 | -13.30 Mn |
| Dec 31, 2022 | -13.30 Mn |
| Sep 30, 2022 | -14.81 Mn |
| Sep 30, 2022 | -14.81 Mn |
| Jun 30, 2022 | -16.02 Mn |
| Jun 30, 2022 | -16.02 Mn |
| Mar 31, 2022 | -10.43 Mn |
| Mar 31, 2022 | -10.43 Mn |
| Dec 31, 2021 | -11.42 Mn |
| Dec 31, 2021 | -11.42 Mn |
| Sep 30, 2021 | -8.59 Mn |
| Sep 30, 2021 | -8.59 Mn |
| Jun 30, 2021 | -8.81 Mn |
| Jun 30, 2021 | -8.81 Mn |
| Mar 31, 2021 | -7.58 Mn |
| Mar 31, 2021 | -7.58 Mn |
| Dec 31, 2020 | -7.33 Mn |
| Dec 31, 2020 | -7.33 Mn |
| Sep 30, 2020 | -7.96 Mn |
| Sep 30, 2020 | -7.96 Mn |
| Jun 30, 2020 | -8.25 Mn |
| Jun 30, 2020 | -8.25 Mn |
| Dec 31, 2019 | -3.64 Mn |
| Dec 31, 2019 | -3.64 Mn |